NJ-SOLIDIA-TECHNOLOGIES
15.10.2020 15:02:08 CEST | Business Wire | Press release
Solidia Technologies® CEO Tom Schuler shared the possibility of turning Solidia Concrete into a carbon sink for the planet during his TED Talk at TED and Future Stewards’ Global Countdown Launch. Tom was invited to "The Countdown," a call to action on climate change, to explain how cement and concrete contribute to the global carbon challenge and the potential impact of new production technologies for Solidia Cement™ and Solidia Concrete™.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201015005299/en/
"To address global warming, innovation in both cement production and carbon utilization are absolutely essential," said Tom. "Our new technology for ready-mix concrete is currently being tested for infrastructure applications. And we have already pushed our research beyond that with a technology that enables concrete to become a carbon sink; that means we consume more carbon dioxide (CO2 ) than we emit during production."
Outlining the issue, he explained how concrete contributes to the global carbon challenge because it is made with cement. "For every ton of cement produced, about a ton of CO2 is released into the atmosphere. As a result, the cement industry is the second largest industrial emitter of CO2 , responsible for about eight percent of global emissions."
By changing the chemistry of cement, Solidia both lowers emissions at the cement plant and consumes CO2 in the production of concrete. "Our cement reacts with CO2 instead of water. During curing, the chemical reaction with our cement breaks apart the CO2 molecules and captures the carbon to make limestone that glues the concrete together.”
For production of precast concrete that is cured in kilns, he explained: “When you combine the emissions reduction during cement production with CO2 consumption during curing, we reduce cement’s carbon footprint by up to 70%.”
Describing the different carbon delivery system developed for ready-mix, he added: "Since we can’t use CO2 gas at a construction site, we had to introduce it into our concrete in solid or liquid form. We are partnering with companies that are turning waste CO2 into a family of chemicals, like oxalic or even citric acid – the same one in orange juice. We use these acids to react with our cement and pack in as much as four times more carbon, resulting in carbon-negative concrete.”
Citing the potential impact, Tom explained: “That means that, in just a few hours, one kilometer of road could permanently consume the same amount of CO2 that nearly 100,000 trees absorb in one year. Thanks to chemistry and waste CO2 , we have the potential to transform concrete – the second most utilized material on the planet – into a carbon sink for the planet.”
About Solidia Technologies®
Based in Piscataway, N.J. (USA), Solidia Technologies® is a cement and concrete technology company that makes it easy and profitable to use CO2 to create superior and sustainable building and construction materials. At scale each year, Solidia can eliminate at least 1.5 gigatonnes of CO₂, save three trillion liters of fresh water, reduce energy consumption equal to ~260 million barrels of oil, and eliminate 100 million tonnes of concrete landfill waste, while engaging industry in a rapid, globally scalable response to some of the greatest threats facing people and planet. Solidia’s investors include Kleiner Perkins , Bright Capital , BASF , BP , Lafarge Holcim , Total Energy Ventures , Oil and Gas Climate Initiative (OGCI) Climate Investments , Air Liquide , Bill Joy and other private investors. Honors include: the 2020, 2019 and 2014 Global Cleantech 100 ; a 2020 and 2014 Best Place to Work in NJ ; 2020, 2019 and 2018 BP Advancing Low Carbon accreditation; the 2019 Solar Impulse 1000 Efficient Solutions ; 2017 ERA Grand Challenge (formerly CCEMC) finalist; 2016 Sustainia 100 ; 2015 NJBiz Business of the Year; 2014 CCEMC Grand Challenge finalist; 2013 R&D Top 100 ; 2013 Katerva Award finalist; and MIT’s Climate CoLab shortlist. Follow Solidia on LinkedIn , Instagram , Twitter , and YouTube .
About TED
TED is a nonprofit organization devoted to Ideas Worth Spreading, often in the form of short talks delivered by leading thinkers and doers. Many of these talks are given at TED conferences, intimate TED Salons and thousands of independently organized TEDx events around the world. Videos of these talks are made available, free, on TED.com and other platforms. Audio versions of TED Talks are published to TED Talks Daily , available on all podcast platforms.
Follow TED on Twitter , Facebook , Instagram and on LinkedIn . Connect at Countdown@ted.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201015005299/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
